Clinical Trial Update: Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating lorlatinib as neoadjuvant therapy for stage IB-IIIB ALK-rearranged non-small cell lung cancer; the study status is no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Neoadjuvant Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING